H.C. Wainwright's Review of Kyverna Therapeutics
Wednesday, 3 July 2024, 19:19
H.C. Wainwright's Analysis on Kyverna Therapeutics
H.C. Wainwright recently initiated coverage on Kyverna Therapeutics (KYTX) with a neutral rating and $8 price target.
Key Points:
- Neutral Rating: H.C. Wainwright started coverage with a neutral outlook.
- Price Target: The firm set a price target of $8 for Kyverna.
- Waiting for Data: More data is needed to fully assess Kyverna's potential.
In summary, the analysis provides detailed insights into H.C. Wainwright's assessment of Kyverna, offering valuable information for investors.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.